

December 14, 2010



Stellar Biotechnologies Receives Extension of NSF -- TECP Grant

PORT HUENEME, CA -- (MARKET WIRE) -- 12/14/10 -- Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF) is pleased to announce that its U.S. subsidiary has been awarded a \$99,000 grant from The National Science Foundation (NSF) through the prestigious Technology Enhancement for Commercial Partnerships (TECP) program. The grant is an extension to the company's SBIR grant: "Megathura Crenulata (giant keyhole limpet) Post Larval Culture -- Bottleneck for a Valuable Medical Resource", and was based on the strong support provided by Bayer Innovation, co-development partner on this project.

John Sundsmo, Ph. D., Stellar's VP, Research & IP Management, commented, "This grant expands the scope of our 2009 \$470,000 award to include critical research that will enhance Stellar's commercial partnerships. The research advances IP for Stellar, and puts us in excellent position for more significant grants to advance the commercial development of this important scientific work, while creating a sustainable supply of the sole KLH source, the keyhole limpet."

Stellar also announces an interview with CEO, Frank Oakes, and Executive VP, Darrell Brookstein: <http://www.pinnacledigest.com/podcast/interview-stellar-biotechnologies-ceo-and-vp-big-pharma-interest-little-market-cap-company>

Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF) (www.StellarBiotechnologies.com) is a world leader in sustainable manufacturing of pharmaceutical grade immune carrier proteins (ICP), particularly with regard to the present most important pharmaceutical protein in this class, KLH (Keyhole Limpet Hemocyanin). This evolutionary protein has a highly complex structure that makes it ideal for use in human and animal vaccines and diagnostic products. With partners and customers, its flagship Stellar KLH products are in the clinic, and on the way to being established as the only sustainable, long-term pharmaceutical source.

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider accepts

responsibility for the adequacy or accuracy of these releases.

Contact:

Darrell Brookstein

dbrookstein@stellarbiotech.com